Cosciens Biopharma Inc
CSCI
Company Profile
Business description
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.
Contact
c/o Norton Rose Fulbright Canada LLP
222 Bay Street, Suite 3000
P.O. Box 53
TorontoONM5K 1E7
CANT: +1 843 900-3223
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
40
Stocks News & Analysis
stocks
Strong finish to the year for overvalued ASX share
A great fiscal 2025 but investors are ahead of themselves.
stocks
Our three most overvalued ASX shares
These three companies are trading at a significant premium to our fair value.
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,080.70 | 39.80 | -0.44% |
| CAC 40 | 7,785.31 | 50.47 | 0.65% |
| DAX 40 | 23,834.17 | 27.04 | 0.11% |
| Dow JONES (US) | 45,514.95 | 114.09 | 0.25% |
| FTSE 100 | 9,246.48 | 25.04 | 0.27% |
| HKSE | 25,913.64 | 279.73 | 1.09% |
| NASDAQ | 21,798.70 | 98.31 | 0.45% |
| Nikkei 225 | 43,459.29 | 184.52 | -0.42% |
| NZX 50 Index | 13,253.73 | 27.41 | -0.21% |
| S&P 500 | 6,495.15 | 13.65 | 0.21% |
| S&P/ASX 200 | 8,803.50 | 37.40 | -0.42% |
| SSE Composite Index | 3,807.29 | 19.55 | -0.51% |